论文部分内容阅读
采用免疫组化Ｓ－Ｐ对新辅助化疗（ＮＡＣＴ）前后宫颈癌组织中增殖细胞核抗原（ＰＣＮＡ）表达进行检测，以探讨ＮＡＣＴ对肿瘤细胞增殖状态的影响。结果发现宫颈癌ＮＡＣＴ后ＰＣＮＡ积分显著低于ＮＡＣＴ前（Ｐ＜０．０５）；临床有效者ＮＡＣＴ前后ＰＣＮＡ积分有显著性差异（Ｐ＜０．０５），而临床无效者ＮＡＣＴ前后则差异不显著（Ｐ＞０．０５）；临床有效、无效者ＮＡＣＴ前ＰＣＮＡ积分相比也无显著差异（Ｐ＞０．０５）。提示ＮＡＣＴ对宫颈癌细胞的增殖具有明显的抑制作用，ＰＣ－ＮＡ可作为恶性肿瘤药物治疗效果评价的一种重要参考指标。
The expression of proliferating cell nuclear antigen (PCNA) in cervical cancer tissues before and after neoadjuvant chemotherapy (NACT) was detected by immunohistochemical S-P to explore the effect of NACT on the proliferation of tumor cells. The results showed that the PCNA score of cervical cancer after NACT was significantly lower than that before NACT (P <0.05); PCNA score of patients with clinically effective NACT was significantly different (P <0.05), but not significantly different after NACT (P> 0.05). There was no significant difference between preoperative PCNA score and clinical effective and ineffective (P> 0.05). It is suggested that NACT can significantly inhibit the proliferation of cervical cancer cells, and PC-NA can be used as an important reference for evaluating the therapeutic effect of malignant tumors.